|
|
|
Insider
Information: |
Higgins John L |
Relationship: |
Director |
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
2,806,928 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$49,664,092 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
2,806,928 |
|
|
Total
Value |
$49,664,092 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
11
|
Stock
price went up :
|
0
|
5
|
Stock
price went down : |
0
|
6
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
-38.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
![](../../../Gifs/iconPlus.jpg) |
Ligand Pharmaceuticals Inc |
LGND |
Director |
2022-12-28 |
417,695 |
2007-02-01 |
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Techne Corp |
TECH |
Director |
2024-05-14 |
36,608 |
2013-10-31 |
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
OmniAb, Inc |
OABI |
Director |
2024-01-30 |
2,352,625 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
165 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
15,553 |
248,018 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-01-27 |
4 |
OE |
$14.47 |
$1,236,400 |
D/D |
70,000 |
273,422 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-01-27 |
4 |
AS |
$182.00 |
$7,280,000 |
D/D |
(40,000) |
243,422 |
0 |
% |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,608 |
286,030 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-02-05 |
4 |
D |
$203.03 |
$602,999 |
D/D |
(2,970) |
343,060 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-02-05 |
4 |
OE |
$10.05 |
$1,394,017 |
D/D |
114,666 |
346,030 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-02-05 |
4 |
AS |
$203.40 |
$11,119,239 |
D/D |
(54,666) |
286,030 |
0 |
% |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-02-15 |
4 |
D |
$172.46 |
$898,862 |
D/D |
(5,212) |
337,848 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-06-30 |
4 |
A |
$85.91 |
$21,220 |
D/D |
247 |
338,095 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-11-12 |
4 |
S |
$160.50 |
$481,500 |
D/D |
(3,000) |
335,095 |
0 |
% |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-01-26 |
4 |
D |
$113.68 |
$1,050,744 |
D/D |
(9,243) |
349,018 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
23,166 |
358,261 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-02-15 |
4 |
D |
$123.68 |
$732,557 |
D/D |
(5,923) |
340,593 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-05-09 |
4 |
OE |
$21.92 |
$175,360 |
D/D |
8,000 |
348,593 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-06-30 |
4 |
A |
$75.84 |
$12,437 |
D/D |
164 |
369,180 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-09-15 |
4 |
S |
$90.00 |
$180,000 |
D/D |
(2,000) |
367,180 |
0 |
% |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-09-16 |
4 |
S |
$89.35 |
$268,050 |
D/D |
(3,000) |
364,180 |
0 |
% |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-09-16 |
4/A |
S |
$88.06 |
$88,060 |
D/D |
(1,000) |
366,180 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
45,922 |
424,731 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-11-17 |
4 |
AS |
$78.32 |
$783,173 |
D/D |
(10,000) |
416,731 |
0 |
% |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-11-18 |
4 |
OE |
$12.78 |
$127,800 |
D/D |
10,000 |
426,731 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-11-30 |
4 |
D |
$72.90 |
$714,639 |
D/D |
(9,803) |
416,928 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2022-12-12 |
4 |
D |
$64.80 |
$255,571 |
D/D |
(3,944) |
432,984 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2022-12-12 |
4 |
OE |
$12.78 |
$255,600 |
D/D |
20,000 |
436,928 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2022-12-16 |
4 |
AS |
$61.87 |
$618,657 |
D/D |
(10,000) |
422,984 |
0 |
% |
|
165 Records found
|
|
Page 5 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|